Back to top
more

Inogen (INGN)

(Delayed Data from NSDQ)

$6.54 USD

6.54
223,956

+0.33 (5.31%)

Updated Aug 4, 2025 03:59 PM ET

After-Market: $6.54 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Inogen (INGN) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Inogen Stock Gains Following Solid Preliminary Q4 Revenues

by Zacks Equity Research

INGN's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.

Zacks Equity Research

Inogen Stock Rises as FDA Clears SIMEOX 200 Airway Clearance Device

by Zacks Equity Research

INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device.

Zacks Equity Research

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Zacks Equity Research

The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen

by Zacks Equity Research

Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.

Indrajit Bandyopadhyay headshot

5 Medical Device Stocks That Survived the 2024 Market Volatility

by Indrajit Bandyopadhyay

Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.

Zacks Equity Research

Inogen (INGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Inogen (INGN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Equity Research

INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up

by Zacks Equity Research

Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sales.

Zacks Equity Research

Inogen (INGN) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Inogen (INGN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Inogen (INGN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 50.98% and 6.16%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of 16.67% and 9.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Zacks Equity Research

Inogen Stock Rises 47% in 6 Months: What's Driving the Rally?

by Zacks Equity Research

INGN shows impressive momentum, driven by strong sales growth, an expanding product portfolio and significant advancements in portable oxygen technology.

Zacks Equity Research

Here's Why You Should Add Inogen Stock to Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for the INGN stock.

Zacks Equity Research

Can HITI Stock Get a Boost From Bricks-and-Mortar Sales in Q3 Earnings?

by Zacks Equity Research

Given High Tide's progress in executing its strategic initiatives, we expect it to report robust Q3 bricks-and-mortar segment sales.

Zacks Equity Research

Inogen (INGN) Rises 127% Year to Date: What's Driving the Stock?

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for the Inogen (INGN) stock.

Zacks Equity Research

Inogen (INGN) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Inogen's (INGN) second-quarter 2024 results reflect significant improvement in the top and bottom lines, driven by strong international and domestic business-to-business sales.

Zacks Equity Research

Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 55.56% and 7.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Penumbra (PEN) Soars 3.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

OrthoPediatrics (KIDS) Soars 7.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

OrthoPediatrics (KIDS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.

Zacks Equity Research

Charles River (CRL) Advances in T-Cell Therapy With New Alliance

by Zacks Equity Research

Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.

Zacks Equity Research

Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ

by Zacks Equity Research

KARL STORZ is set to acquire all of the outstanding shares of Asensus Surgical (ASXC) for $0.35 per share in cash, making Asensus a subsidiary of KARL STORZ.

Zacks Equity Research

Inogen (INGN) Down 0.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.